Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Related Posts
Alphabet expects ‘slight headwind’ to ads business this year, executives say
The comments come as Alphabet and other tech companies prepare to pay up due to the Trump administration’s trade policies.
Silicon Valley’s turn of fortune: Intel has worst year ever, while Broadcom enjoys record gain
Intel lost over 60% of its value in 2024, the biggest drop in its 53 years as a public company. Broadcom’s stock price more than […]
Coca-Cola tops earnings estimates, as higher prices offset sluggish demand
Shares of Coke have climbed 18% this year, raising the company’s market value to nearly $300 billion.